Modification of viral myocarditis in mice by interleukin-6

Circulation Research

Volumn 78, Issue 5, 1996, Pages 848-856

  Kanda, Tsugiyasu ^a   Wilson McManus, Janet E ^c   Nagai, Ryozo ^a   Imai, Susumu ^a   Suzuki, Tadashi ^b   Yang, DeCheng ^c   McManus, Brace M ^c   Kobayashi, Isao ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

host immunity; in situ hybridization; interleukin 6; myocarditis

Indexed keywords

CYTOKINE; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALOMYOCARDITIS VIRUS; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KILLER CELL; LYMPHOCYTIC INFILTRATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS MYOCARDITIS; VIRUS REPLICATION;

EID: 9244227127     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.78.5.848     Document Type: Article

References (41)

1. Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, Jacobsen H, Kirchner H. Antiviral effects of recombinant tumor necrosis factor in vitro. Nature. 1987;323:816-819.
2. Rook AH, Masur H, Lane C, Frederick W, Kasahara T, Macher AM, Djen JY, Manischeurtz JF, Jackson L, Fauci AS, Quinnan GU Jr. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest. 1983;72:398-403.
3. Weissenbach J, Chernajovsky Y, Zeevi M, Shulman L, Soreq H, Nir H, Wallach D, Perricandet M, Tiollais P, Revel M. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A. 1980;77:7152-7156.
4. 3 infection in mice by exogenous administration of interleukin-1 and interleukin-2. J Virol. 1994;68: 195-206.
5. Yamada T, Matsumori A, Sasayama S. Therapeutic effect of antitumor necrosis factor-α antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation. 1994;89:846-851.
6. Matsumori A, Yamada T, Kawai C. Immunomodulating therapy in viral myocarditis: effects of tumor necrosis factor, interleukin-2 and anti-interleukin-2 receptor antibody in an animal model. Eur Heart J. 1991;12(suppl D):203-205.
7. Kishimoto C, Kuroki Y, Hiraoka Y, Ochiai H, Kurokawa M, Sasayama S. Cytokine and murine coxsackie virus B3 myocarditis: interleukins suppress myocarditis in the acute stage but enhance the condition in the subsequent stage. Circulation. 1994;89:2836-2842.
8. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Imamatsu A, Tsunasawa S, Sakiyama F, Matsui H, Tokuhara Y, Taniguchi T, Kishimoto T. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986;324:73-77.
9. Lots M, Jirik F, Kabouridis R, Tsoukas C, Hirano T, Kishimoto T, Carson DA. BSF-2/IL-6 is costimulant for human thymocytes and T-lymphocytes. J Exp Med. 1988;140:508-513.
10. Mule JJ, McIntosh JK, Joblons DM, Rosenberg SA. Antitumor activity of recombinant interleukin-6 in mice. J Exp Med. 1990;171: 629-635.
11. Gauldie JC, Richards C, Harnich D, Lansdrop P, Baumann H. Interferon β2/BSF-2 shares identity with monocyte-derived hepatocyte stimulating factor (HSF) and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A. 1987;84:7251-7256.
12. Luger TA, Krutmann J, Kirnbaner R, Vrbarski A, Schwarz T, Klappacher G, Kock A, Mickche M, Malejczyk J, Schauer E, May LA, Sehgel PB. IFN-β2/IL-6 augments the activity of human natural killer cells. J Immunol. 1989;143:1206-1210.
13. Tilg H, Trehr E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 as an antiinflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113-118.
14. Yokoyama T, Kanda T, Suzuki T, Murata K. Combination therapy of OK432 and recombinant human interferon-a A/D on viral myocarditis in mice starting after infection. J Pharmacol Exp Ther. 1991; 258:1114-1119.
15. 3 against viral myocarditis in mice. Arzneimittelforschung. 1993;43:80-83.
16. Takatsuki F, Okano A, Suzuki C, Chieda R, Takahara Y, Hirano T, Kishimoto T, Hamuro J, Akiyama Y. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J Immunol. 1989;141:3072-3077.
17. Takatsuki F, Okano A, Suzuki C, Miyasaka Y, Hirano T, Kishimoto T, Ejima D, Akiyama Y. Interleukin-6 perfusion stimulates reconstitution of the immune and hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 1990;50:2885-2890.
18. Wilson JE, Yang DC, Zeheb R, Anderson DA, Bondy GP, McManus BM. In situ hybridization for viral RNA: a comparison of manual and automated methods. FASEB J. 1995;9:A970. Abstract.
19. Chow LH, Beisel KW, McManus BM. Enteroviral infection of mice with severe combined immunodeficiency: evidence for direct viral pathogenesis of myocardial injury. Lab Invest. 1992;66:24-31.
20. Yokoyama T, Kanda T, Suzuki T, Murata K. Enhancement of myocardial damage and alteration of lymphocyte subsets in murine model of postpartum myocarditis. Am J Cardiovasc Pathol. 1993;4: 343-351.
21. 3-induced myocarditis in resistant B10A mice. J Exp Med. 1992; 175:1123-1129.
22. Dong R, Liu P, Wee L, Butany J, Sole MJ. Verapamil ameliorates the clinical and pathological course of murine myocarditis. J Clin Invest. 1992;90:2022-2030.
23. Mule JJ, Custer MC, Travis WD, Rosenberg SA. Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol. 1992;148:2622-2629.
24. Wong GG, Clark SC. Multiple actions of interleukin-6 within a cytokine network. Immunol Today. 1988;9:137-139.
25. Puri PK, Lenard P. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo. Lymphokine Res. 1992;11:133-139.
26. Castell JV, Geiger T, Gross V, Andus T, Walter E, Hirano T, Kishimoto T, Heinrich PC. Plasma clearance organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem. 1988;177:357-361.
27. 3-induced production of tumor necrosis factor-a, IL-1β3 and IL-6 in human monocyte. J Immunol. 1992;148: 2270-2277.
28. Youker K, Smith CW, Miller D, Michael LH, Rossen RD, Anderson DC, Entman ML. Neutrophil adherence to isolated adult canine myocyte: induction by cardiac lymph collected during ischemia and reperfusion. J Clin Invest. 1992;89:602-609.
29. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo T. Intratracheal injection of endotoxin and cytokines, II: interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol. 1991;138:1097-1101.
30. Barton BE, Jackson JV. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun. 1993;61:1496-1500.
31. 3-induced myocarditis in resistant B10 A mice. J Exp Med. 1992;175:1123-1129.
32. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol. 1981;143:3517-3522.
33. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Danarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990;75:40-44.
34. Muraguchi A, Hirano T, Matsuda T, Horii K, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988;167:332-339.
35. Wolfgram LJ, Beisel KW, Herskowitz A, Rose NR. Variations in the susceptibility to coxsackie virus B3-induced myocarditis among different strains of mice. J Immunol. 1986;136:1846-1852.
36. Kishimoto C, Thorp KA, Abelmann WH. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine coxsackie virus B3 myocarditis. Circulation. 1990;82:982-987.
37. Woodruff JF. Viral myocarditis: a review. Am J Pathol. 1980;101: 425-431.
38. 2:HPGF). EMBO J. 1987;6:1219-1225.
39. Seko Y, Shinkai Y, Kawasaki A, Yagita H, Okumura K, Takaku F, Yazaki Y. Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by coxsackie virus B3. Circulation. 1991;84:788-795.
40. Matsui S, Matsumori A, Matoba Y, Uchida A. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest. 1994;94:1212-1217.
41. Letvin NL, Kanffman RS, Finberg R. An adherent cell lysis virus infected targets: characterization, activation and fine specificity of the cytotoxic cell. J Immunol. 1982;129:2396-2401.